News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,598 Results
Type
Article (43050)
Company Profile (267)
Press Release (698268)
Multimedia
Podcasts (107)
Webinars (20)
Section
Business (207425)
Career Advice (2155)
Deals (36054)
Drug Delivery (141)
Drug Development (82173)
Employer Resources (176)
FDA (16628)
Job Trends (15095)
News (350790)
Policy (33187)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2643)
Accelerated approval (55)
ADA (46)
Adcomms (29)
Allergies (190)
Alliances (49937)
ALS (225)
Alzheimer's disease (1845)
Antibody-drug conjugate (ADC) (506)
Approvals (17062)
Artificial intelligence (719)
ASCO (328)
Autoimmune disease (334)
Automation (60)
Bankruptcy (368)
Best Places to Work (11691)
BIOSECURE Act (20)
Biosimilars (232)
Biotechnology (171)
Bladder cancer (202)
Brain cancer (74)
Breast cancer (791)
Cancer (6237)
Cardiovascular disease (498)
Career advice (1835)
Career pathing (45)
CAR-T (351)
CDC (60)
Celiac Disease (3)
Cell therapy (951)
Cervical cancer (54)
Clinical research (71808)
Collaboration (2179)
Commercialization (1)
Company closure (6)
Compensation (1480)
Complete response letters (86)
COVID-19 (2793)
CRISPR (114)
C-suite (1236)
Cystic fibrosis (156)
Data (8553)
Decentralized trials (3)
Denatured (32)
Depression (176)
Dermatology (95)
Diabetes (662)
Diagnostics (7050)
Digital health (63)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (356)
Drug pricing (205)
Drug shortages (33)
Duchenne muscular dystrophy (304)
Earnings (93331)
Editorial (71)
Employer branding (21)
Employer resources (155)
Events (121569)
Executive appointments (1138)
FDA (20562)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (35)
Funding (1834)
Gene editing (242)
Generative AI (60)
Gene therapy (753)
GLP-1 (1104)
Government (4853)
Grass and pollen (6)
Guidances (415)
Healthcare (19328)
Hematology (193)
HIV (88)
Huntington's disease (61)
IgA nephropathy (110)
Immunology and inflammation (299)
Immuno-oncology (103)
Indications (210)
Infectious disease (3161)
Inflammatory bowel disease (221)
Inflation Reduction Act (14)
Influenza (142)
Intellectual property (315)
Interviews (343)
IPO (16821)
IRA (50)
Job creations (3694)
Job search strategy (1518)
JPM (59)
Kidney cancer (20)
Labor market (110)
Layoffs (581)
Leadership (42)
Legal (8080)
Liver cancer (103)
Longevity (35)
Lung cancer (823)
Lymphoma (470)
Machine learning (63)
Management (59)
Manufacturing (1141)
Marketing (1)
MASH (210)
Medical affairs (1)
Medical device (14071)
Medtech (14235)
Mergers & acquisitions (20535)
Metabolic disorders (1643)
mRNA (230)
Multiple sclerosis (198)
NASH (17)
Neurodegenerative disease (455)
Neuropsychiatric disorders (111)
Neuroscience (3473)
Neurotech (1)
NextGen: Class of 2026 (6583)
Non-profit (4578)
Now hiring (81)
Obesity (754)
Opinion (304)
Ovarian cancer (236)
Pain (264)
Pancreatic cancer (347)
Parkinson's disease (393)
Partnered (35)
Patents (633)
Patient recruitment (735)
Peanut (66)
People (60810)
Pharmaceutical (61)
Pharmacy benefit managers (35)
Phase 1 (22394)
Phase 2 (31641)
Phase 3 (23540)
Pipeline (9640)
Policy (334)
Postmarket research (2613)
Preclinical (9529)
Press Release (66)
Prostate cancer (334)
Psychedelics (60)
Radiopharmaceuticals (349)
Rare diseases (1155)
Real estate (6032)
Recruiting (72)
Regulatory (25949)
Reports (56)
Research institute (2450)
Resumes & cover letters (366)
Rett syndrome (42)
RNA editing (24)
RSV (90)
Schizophrenia (186)
Series A (311)
Series B (228)
Service/supplier (11)
Sickle cell disease (118)
Special edition (26)
Spinal muscular atrophy (169)
Sponsored (48)
Startups (3698)
State (2)
Stomach cancer (18)
Supply chain (135)
Tariffs (88)
The Weekly (73)
Vaccines (1156)
Venture capital (120)
Weight loss (485)
Women's health (136)
Worklife (20)
Date
Last 7 days (504)
Last 30 days (2439)
Last 365 days (30543)
2026 (15601)
2025 (30380)
2024 (35458)
2023 (40355)
2022 (51465)
2021 (55987)
2020 (54426)
2019 (46944)
2018 (35374)
2017 (32487)
2016 (31930)
2015 (37948)
2014 (31731)
2013 (26770)
2012 (29002)
2011 (29676)
2010 (27738)
Location
Africa (774)
Alabama (93)
Alaska (7)
Arizona (366)
Arkansas (15)
Asia (40715)
Australia (6695)
California (13924)
Canada (3926)
China (1474)
Colorado (603)
Connecticut (615)
Delaware (433)
Europe (88402)
Florida (2092)
Georgia (447)
Hawaii (3)
Idaho (63)
Illinois (1137)
India (97)
Indiana (627)
Iowa (24)
Japan (590)
Kansas (133)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1653)
Massachusetts (9993)
Michigan (375)
Minnesota (750)
Mississippi (6)
Missouri (147)
Montana (33)
Nebraska (30)
Nevada (148)
New Hampshire (85)
New Jersey (3665)
New Mexico (30)
New York (3648)
North Carolina (1766)
North Dakota (9)
Northern California (7017)
Ohio (420)
Oklahoma (23)
Oregon (42)
Pennsylvania (2762)
Puerto Rico (31)
Rhode Island (52)
South America (1140)
South Carolina (86)
South Dakota (2)
Southern California (5522)
Tennessee (224)
Texas (2224)
United States (49148)
Utah (414)
Vermont (2)
Virginia (341)
Washington D.C. (83)
Washington State (1107)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
741,598 Results for "rapamycin holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 3, 2026
·
8 min read
Press Releases
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
April 28, 2026
·
6 min read
Press Releases
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
April 28, 2026
·
6 min read
Press Releases
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
March 16, 2026
·
8 min read
Press Releases
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 4, 2026
·
9 min read
Press Releases
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
February 24, 2026
·
14 min read
Press Releases
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
February 24, 2026
·
2 min read
Press Releases
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026
·
9 min read
Press Releases
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
May 21, 2026
·
12 min read
Press Releases
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 20, 2026
·
6 min read
1 of 74,160
Next
